To evaluate the potential of promoter profiling for assessing ALN status, we used WGS to characterize the promoter profiling of cfDNA derived from 330 breast cancer patients collected from January 2018 to December 2019, including 162 ALN-positive and 168 ALN-negative patients. Here, ARLN is linked to breast cancer.